Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...
The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...
In the UK, cancer rates in 25 to 49-year-olds increased by 22 per cent in the last three decades, the biggest change in any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback